These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

922 related items for PubMed ID: 11686357

  • 1. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A, Casilli F, Assanelli E, Grazi M, Marenzi G, Guazzi MD.
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [Abstract] [Full Text] [Related]

  • 2. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Théroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A.
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [Abstract] [Full Text] [Related]

  • 3. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M.
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [Abstract] [Full Text] [Related]

  • 4. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [Abstract] [Full Text] [Related]

  • 5. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D.
    Circulation; 2004 Jul 27; 110(4):392-8. PubMed ID: 15249498
    [Abstract] [Full Text] [Related]

  • 6. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
    Vila V, Martínez-Sales V, Réganon E, Peris E, Perez F, Ruano M, Aznar J.
    Haematologica; 2001 Jul 27; 86(7):729-34. PubMed ID: 11454528
    [Abstract] [Full Text] [Related]

  • 7. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F.
    N Engl J Med; 1997 Aug 14; 337(7):447-52. PubMed ID: 9250846
    [Abstract] [Full Text] [Related]

  • 8. Enoxaparin in acute coronary syndromes.
    Lee S, Gibson CM.
    Expert Rev Cardiovasc Ther; 2007 May 14; 5(3):387-99. PubMed ID: 17489664
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S, Morrow DA, Sloan S, Antman EM, Sabatine MS.
    Circulation; 2009 Mar 10; 119(9):1195-202. PubMed ID: 19237657
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
    Hoppensteadt D, Fareed J, Klein AL, Jasper SE, Apperson-Hansen C, Lieber EA, Katz WE, Malouf JF, Stoddard MF, Pape LA, Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Investigators.
    Am J Cardiol; 2008 Oct 01; 102(7):842-6. PubMed ID: 18805108
    [Abstract] [Full Text] [Related]

  • 16. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
    Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, López-Sendón JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E, ExTRACT-TIMI 25 Investigators.
    N Engl J Med; 2006 Apr 06; 354(14):1477-88. PubMed ID: 16537665
    [Abstract] [Full Text] [Related]

  • 17. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM, Petersen JL, Hasselblad V, Mahaffey KW, Ferguson JJ.
    Am Heart J; 2005 Apr 06; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [Abstract] [Full Text] [Related]

  • 18. The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes.
    Nguyen-Ho P, Levine GN.
    Panminerva Med; 2002 Jun 06; 44(2):115-22. PubMed ID: 12032429
    [Abstract] [Full Text] [Related]

  • 19. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jolly S, Granger CB, Fox KA, Bassand JP, Yusuf S, OASIS 5 and 6 Investigators.
    Circulation; 2008 Nov 11; 118(20):2038-46. PubMed ID: 18955665
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.